EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Viral anti‐inflammatory serpin reduces immuno‐coagulopathic pathology in SARS‐CoV‐2 mouse models of infection

Liqiang Zhang, Yize Henry Li iD, Karen Kibler iD, Simona Kraberger, Arvind Varsani, Julie Turk, Nora Elmadbouly, Emily Aliskevich, Laurel Spaccarelli, Bereket Estifanos, Junior Enow, Isabela Rivabem Zanetti iD und 20 weitere

EMBO Molecular Medicine · 2023

DOI: 10.15252/emmm.202317376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Liqiang Zhang und 31 weiteren Autor:innen. Beteiligte Einrichtung: Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA. Hauptthemen laut MEDLINE: Serpins, COVID-19, Respiratory Distress Syndrome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIAMS NIH HHS, ASU Skysong Innovation Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SARS‐CoV‐2 acute respiratory distress syndrome (ARDS) induces uncontrolled lung inflammation and coagulopathy with high mortality. Anti‐viral drugs and monoclonal antibodies reduce early COVID‐19 severity, but treatments for late‐stage immuno‐thrombotic syndromes and long COVID are limited. Serine protease inhibitors (SERPINS) regulate activated proteases. The myxoma virus‐derived Serp‐1 protein is a secreted immunomodulatory serpin that targets activated thrombotic, thrombolytic, and complement proteases as a self‐defense strategy to combat clearance. Serp‐1 is effective in multiple animal models of inflammatory lung disease and vasculitis. Here, we describe systemic treatment with purified PEGylated Serp‐1 as a therapy for immuno‐coagulopathic complications during ARDS. Treatment with PEGSerp‐1 in two mouse‐adapted SARS‐CoV‐2 models in C57Bl/6 and BALB/c mice reduced lung and heart inflammation, with improved outcomes. PEGSerp‐1 significantly reduced M1 macrophages in the lung and heart by modifying urokinase‐type plasminogen activator receptor (uPAR), thrombotic proteases, and complement membrane attack complex (MAC). Sequential changes in gene expression for uPAR and serpins (complement and plasminogen inhibitors) were observed. PEGSerp‐1 is a highly effective immune‐modulator with therapeutic potential for severe viral ARDS, immuno‐coagulopathic responses, and Long COVID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SerpinsCOVID-19Respiratory Distress SyndromeMiceAnimalsHumansSARS-CoV-2Post-Acute COVID-19 SyndromeAnti-Inflammatory AgentsDisease Models, AnimalPeptide Hydrolases

Stichwörter der Autor:innen

SARS-CoV-2complementinflammationserpinuPAR

Substanzen

SerpinsAnti-Inflammatory AgentsPeptide Hydrolases

Autor:innen und Institutionen

  • Center for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.
  • Center of Immunotherapy, Vaccines and Virotherapy, Biodesign Institute, Arizona State University, Tempe, AZ, USA.
  • School of Life Sciences, Arizona State University, Tempe, AZ, USA.
  • Center of Fundamental and Applied Microbiomics, Biodesign Institute, Arizona State University, Tempe, AZ, USA.
  • Center for Evolution and Medicine, School of Life Sciences, Arizona State University, Tempe, AZ, USA.
  • Departments of Pathology & Lab Medicine, Yale-New Haven Hospital, New Haven, CT, USA.

ORCID-Profile: Yize Henry Li, Karen Kibler, Isabela Rivabem Zanetti, Jessika Schlievert, Henna Monder, Rohan Saju, Masmudur Rahman, Grant McFadden, Brenda G Hogue, Alexandra R Lucas

Förderung

  • NIAID NIH HHS
  • NIAMS NIH HHS
  • ASU Skysong Innovation Award
  • HHS ¦ National Institutes of Health
  • Mercatus Center Fast Grant

Zitieren

APA

Zhang, L., Li, Y. H., Kibler, K., Kraberger, S., Varsani, A., Turk, J., Elmadbouly, N., Aliskevich, E., Spaccarelli, L., Estifanos, B., Enow, J., Zanetti, I. R., Saldevar, N., Lim, E., Schlievert, J., Browder, K., Wilson, A., Juan, F. A., Pinteric, A., …, & Lucas, A. R. (2023). Viral anti‐inflammatory serpin reduces immuno‐coagulopathic pathology in SARS‐CoV‐2 mouse models of infection. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202317376

Vancouver

Zhang L, Li YH, Kibler K, Kraberger S, Varsani A, Turk J, et al. Viral anti‐inflammatory serpin reduces immuno‐coagulopathic pathology in SARS‐CoV‐2 mouse models of infection. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202317376

BibTeX
@article{Zhang2023,
  author = {Zhang, Liqiang and Li, Yize Henry and Kibler, Karen and Kraberger, Simona and Varsani, Arvind and Turk, Julie and Elmadbouly, Nora and Aliskevich, Emily and Spaccarelli, Laurel and Estifanos, Bereket and Enow, Junior and Zanetti, Isabela Rivabem and Saldevar, Nicholas and Lim, Efrem and Schlievert, Jessika and Browder, Kyle and Wilson, Anjali and Juan, Fernando Arcos and Pinteric, Aubrey and Garg, Aman and Monder, Henna and Saju, Rohan and Gisriel, Savanah and Jacobs, Bertram and Karr, Timothy L and Florsheim, Esther Borges and Kumar, Vivek and Wallen, John and Rahman, Masmudur and McFadden, Grant and Hogue, Brenda G and Lucas, Alexandra R},
  title = {Viral anti‐inflammatory serpin reduces immuno‐coagulopathic pathology in SARS‐CoV‐2 mouse models of infection},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  doi = {10.15252/emmm.202317376}
}
Kostenlos starten →